{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:08:19Z","timestamp":1785186499604,"version":"3.55.0"},"reference-count":34,"publisher":"The Endocrine Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,10,1]]},"DOI":"10.1210\/jc.2007-1403","type":"journal-article","created":{"date-parts":[[2008,8,6]],"date-time":"2008-08-06T03:48:58Z","timestamp":1217994538000},"page":"3777-3784","source":"Crossref","is-referenced-by-count":137,"title":["Increased Prevalence of Tricuspid Regurgitation in Patients with Prolactinomas Chronically Treated with Cabergoline"],"prefix":"10.1210","volume":"93","author":[{"given":"Annamaria","family":"Colao","sequence":"first","affiliation":[{"name":"Department of Molecular and Clinical Endocrinology and Oncology (A.C., A.D.S., M.Gac., M.D., E.G., R.P., G.Lo.) Section of Cardioangiology, Federico II University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Galderisi","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, and Department of Clinical and Experimental Medicine (M.Gal., M.P., G.Le.) Section of Cardioangiology, Federico II University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Di Sarno","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Endocrinology and Oncology (A.C., A.D.S., M.Gac., M.D., E.G., R.P., G.Lo.) Section of Cardioangiology, Federico II University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moira","family":"Pardo","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, and Department of Clinical and Experimental Medicine (M.Gal., M.P., G.Le.) Section of Cardioangiology, Federico II University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gaccione","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Endocrinology and Oncology (A.C., A.D.S., M.Gac., M.D., E.G., R.P., G.Lo.) Section of Cardioangiology, Federico II University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"D'Andrea","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Endocrinology and Oncology (A.C., A.D.S., M.Gac., M.D., E.G., R.P., G.Lo.) Section of Cardioangiology, Federico II University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ermelinda","family":"Guerra","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Endocrinology and Oncology (A.C., A.D.S., M.Gac., M.D., E.G., R.P., G.Lo.) Section of Cardioangiology, Federico II University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Pivonello","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Endocrinology and Oncology (A.C., A.D.S., M.Gac., M.D., E.G., R.P., G.Lo.) Section of Cardioangiology, Federico II University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lerro","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, and Department of Clinical and Experimental Medicine (M.Gal., M.P., G.Le.) Section of Cardioangiology, Federico II University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Lombardi","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Endocrinology and Oncology (A.C., A.D.S., M.Gac., M.D., E.G., R.P., G.Lo.) Section of Cardioangiology, Federico II University of Naples, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"key\n\t\t\t\t2019041114084559700_R1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas.","volume":"5","author":"Gillam","year":"2006","journal-title":"Endocr Rev"},{"key":"key\n\t\t\t\t2019041114084559700_R2","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMcp043908","article-title":"Diagnosis and initial management of Parkinson\u2019s disease.","volume":"353","author":"Nutt","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041114084559700_R3","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMcp021288","article-title":"Restless legs syndrome.","volume":"348","author":"Earley","year":"2003","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"key\n\t\t\t\t2019041114084559700_R4","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1530\/eje.1.02348","article-title":"Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours","volume":"156","author":"Colao","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"key\n\t\t\t\t2019041114084559700_R5","doi-asserted-by":"crossref","first-page":"730","DOI":"10.4065\/78.6.730","article-title":"The US Food and Drug Administration\u2019s registry of patients with pergolide-associated valve heart disease.","volume":"78","author":"Flowers","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"key\n\t\t\t\t2019041114084559700_R6","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(04)15945-X","article-title":"Treatment of Parkinson\u2019s disease with pergolide and relation to restrictive valve heart disease.","volume":"363","author":"Van Camp","year":"2004","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041114084559700_R7","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJM200511033531822","article-title":"Cabergoline-related severe restrictive mitral regurgitation.","volume":"353","author":"Pinero","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041114084559700_R8","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00045415-200211000-00005","article-title":"Fibrotic valve heart disease subsequent to bromocriptine treatment.","volume":"10","author":"Serratrice","year":"2002","journal-title":"Cardiol Rev"},{"key":"key\n\t\t\t\t2019041114084559700_R9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation.","volume":"356","author":"Schade R Andersohn","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041114084559700_R10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valve heart disease and the use of dopamine agonists for Parkinson\u2019s disease.","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041114084559700_R11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0952-8180(01)00353-1","article-title":"Carcinoid heart disease: a case report and literature review.","volume":"14","author":"Botero","year":"2002","journal-title":"J Clin Anesth"},{"key":"key\n\t\t\t\t2019041114084559700_R12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.7326\/0003-4819-117-1-50","article-title":"Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations.","volume":"117","author":"Redfield","year":"1992","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019041114084559700_R13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejphar.2005.03.010","article-title":"Agonism at 5-HT2B receptors is not a class effect of the ergolines.","volume":"513","author":"Jahnichen","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"key\n\t\t\t\t2019041114084559700_R14","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa022657","article-title":"Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.","volume":"349","author":"Colao","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041114084559700_R15","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2265.2007.02905.x","article-title":"Predictors of remission of hyperprolactinemia after long-term withdrawal of cabergoline therapy.","volume":"67","author":"Colao","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key\n\t\t\t\t2019041114084559700_R16","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"key\n\t\t\t\t2019041114084559700_R17","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1210\/jcem.82.11.4368","article-title":"Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.","volume":"82","author":"Colao","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114084559700_R18","first-page":"2247","article-title":"Macroprolactinoma shrinkage during cabergoline treatment is greater in naive than in patients pre-treated with other dopamine agonists: a prospective study in 110 patients.","volume":"85","author":"Colao","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114084559700_R19","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","article-title":"Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition and therapeutic strategy.","volume":"86","author":"Di Sarno","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114084559700_R20","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/00004872-199715070-00006","article-title":"Is insulin action a determinant of left ventricular relaxation in uncomplicated essential hypertension?","volume":"15","author":"Galderisi","year":"1997","journal-title":"J Hypertens"},{"key":"key\n\t\t\t\t2019041114084559700_R21","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1161\/01.CIR.58.6.1072","article-title":"Recommendations regarding quantitation of M-mode echocardiography: results of a survey of echocardiographic measurements.","volume":"58","author":"Sahn","year":"1978","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041114084559700_R22","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0002-9149(86)90771-X","article-title":"Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.","volume":"57","author":"Devereux","year":"1986","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t2019041114084559700_R23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.euje.2005.12.014","article-title":"Recommendations for chamber quantification.","volume":"7","author":"Lang","year":"2006","journal-title":"Eur J Echocardiogr"},{"key":"key\n\t\t\t\t2019041114084559700_R24","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1067\/mje.2002.120202","article-title":"Recommendations of Doppler echocardiography: a report from the Doppler Quantification Task Force of the nomenclature and Standard Committee of the American Society of Echocardiography.","volume":"15","author":"Quinones","year":"2002","journal-title":"J Am Soc Echocardiogr"},{"key":"key\n\t\t\t\t2019041114084559700_R25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0894-7317(14)80414-8","article-title":"A new formula for echo-Doppler estimation of right ventricular systolic pressure.","volume":"7","author":"Pepi","year":"1994","journal-title":"J Am Soc Echocardiogr"},{"key":"key\n\t\t\t\t2019041114084559700_R26","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0894-7317(03)00335-3","article-title":"Recommendations for evaluation of the severity of native valve regurgitation with two-dimensional and Doppler echocardiography.","volume":"16","author":"Zoghbi","year":"2003","journal-title":"J Am Soc Echocardiogr"},{"key":"key\n\t\t\t\t2019041114084559700_R27","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1161\/01.CIR.0000156449.49998.51","article-title":"Tricuspid valve tethering predicts residual tricuspid regurgitation after tricuspid annuloplasty.","volume":"111","author":"Fukuda","year":"2005","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041114084559700_R28","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/eje.0.1480325","article-title":"Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia.","volume":"148","author":"Colao","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"key\n\t\t\t\t2019041114084559700_R29","first-page":"16","article-title":"Dopamine agonists and valve heart disease","volume":"356","author":"Stephens","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041114084559700_R30","doi-asserted-by":"crossref","DOI":"10.1111\/j.1742-1241.2008.01779.x","article-title":"Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia","author":"Bogazzi","year":"2008","journal-title":"Int J Clin Pract"},{"key":"key\n\t\t\t\t2019041114084559700_R31","article-title":"Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas","author":"Vallette","year":"2008","journal-title":"Pituitary"},{"key":"key\n\t\t\t\t2019041114084559700_R32","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2007-2658","article-title":"Aortic valve calcification and mild tricuspid regurgitation, but no clinical heart disease after eight years of dopamine agonist therapy for prolactinoma","author":"Kars","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114084559700_R33","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0002-9149(77)80028-3","article-title":"Pathophysiologic assessment of hypertensive heart disease with echocardiography.","volume":"26","author":"Dunn","year":"1977","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t2019041114084559700_R34","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/01.CIR.91.3.734","article-title":"Determinants of echocardiographic aortic root size. The Framingham Heart Study.","volume":"91","author":"Vasan","year":"1995","journal-title":"Circulation"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/93\/10\/3777\/9053421\/jcem3777.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T04:20:36Z","timestamp":1557721236000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/93\/10\/3777\/2627303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,1]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2007-1403","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,1]]}}}